On September 28, Nanjing Triastek Pharmaceutical Technology Co. Ltd. (hereinafter referred to as “Triastek”) announced the completion of a RMB 150 million Pre-C round of financing. The funds raised will be mainly used to accelerate the clinical research of their 3D printing drug pipeline and the commercialization of this technology. The Pre-C funding round was led by Guoxin Investment ("Guoxin"), with participation from Goldmine Multi-family Office ("Goldmine") and existing investor Mr. Xiaodong Zheng, president of Shanghai Tofflon Science and Technology Co. Ltd. ("Tofflon"). China Renaissance served as exclusive financial advisor for this transaction.

Previously, Triastek has completed six rounds of financing and attracted renowned investors including Tasly Holding Group, Morningside Venture Capital, Volcanics Venture, Dalton Venture, Yunqi Partners, Mr. Xiaodong Zheng, Matrix Partners China, CPE, Shanghai Sci-Tech Innovation Center Capital, and Triwise Capital.

Triastek’s proprietary technology, the Melt Extrusion Deposition (MED®) 3D printing process, combined with digital formulation development methods, enables complex drug delivery and programmed release. Triastek is also actively developing new technology processes, including Semi-Solid Extrusion, Micro-Injection Molding, and Micro-Droplet Jetting. The combination of these technologies with MED offers a wide range of solutions for pharmaceutical delivery and development needs, such as oral peptides, gastric retention, and high potency products.

Triastek, as a leading provider of digital pharmaceutical process technology, is continuously advancing applications of 3D printing technology to produce novel pharmaceutical products that improve patient outcomes. The company has engaged in extensive business collaborations with global pharmaceutical companies, focusing on novel products and advanced technical solutions. Currently, Triastek has established strategic partnerships with Eli Lilly, Merck KGaA, Boehringer Ingelheim, Siemens, and Sperogenix.

With eight years of technological innovation and industry application, Triastek has achieved four notable distinctions in the global pharmaceutical 3D printing industry: First, it leads in patent acquisition, accounting for more than 20% of all applications in the field. Second, it has the largest number of 3D-printed products, with three of its products gaining IND clearancefrom US FDA and one gaining IND from NMPA. Third, it has the highest production capacity for 3D printing drug pipelines, with a self-built production center that meets Good Manufacturing Practice (GMP) standards of continuous 3D printing, with annual production capacity of the first production line reaching 75 million tablets. Fourth, it is the only Chinese pharmaceutical company selected in the US Food and Drug Administration (FDA)'s "Emerging Technology Project (ETP)".